A Randomized, Open-Label, Multicenter, Phase 3 Study Evaluating the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) Plus R-CHP versus Polatuzumab Vedotin plus R-CHP in Treatment-naive Participants with GCB Subtype of Diffuse Large B-Cell Lymphoma (DLBCL) (MK2140-011 (waveline-011))

Principal Investigator

Dr Graham Collins

Contact us

Email: Latephasehaematology@ouh.nhs.uk

IRAS number

1011281